The global imatinib drug market is estimated to grow at a CAGR of around 4% during the forecast period. The major factors contributing to the growth of the market include the rising prevalence of cancer and an increase in awareness programs towards cancer by government and private organizations. Imatinib is a chemotherapy drug that used to slow down or stopping the growth of the cancer cells. This medication is used for the treatment of certain types of cancer including, acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic syndrome. Imatinib drug helps in improving blood count which makes it highly effective and attracting the target patients for the adoption of this drug leading to the significant growth of the imatinib drug market.
Get Free Sample link @ https://www.omrglobal.com/request-sample/imatinib-drug-market
The global imatinib drug market is segmented based on drug form, and application. Based on drug form, the market is classified into tablets and capsules. Based on application the market is classified into blood cancer (leukemia and other blood cancers), gastrointestinal stromal tumors (GIST), skin tumors (dermatofibrosarcoma protuberans), and other tumors such as systemic mastocytosis. Blood cancer segment is expected to hold the major market share owing to increasing demand for imatinib for the treatment of different types of leukemia cancers such as Acute myeloid (or myelogenous) leukemia (AML), Chronic myeloid (or myelogenous) leukemia (CML), Acute lymphocytic (or lymphoblastic) leukemia (ALL), and Chronic lymphocytic leukemia (CLL).
A full report of Imatinib Drug Market available @ https://www.omrglobal.com/industry-reports/imatinib-drug-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Global Imatinib Drug Market by Drug Form
- Tablet
- Capsule
Global Imatinib Drug Market by Application
- Blood Cancer (Leukemia and Other Blood Cancers)
- Gastrointestinal Stromal Tumors (GIST)
- Skin Tumors (Dermatofibrosarcoma Protuberans)
- Other Tumors (Systemic Mastocytosis)
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Rest of the World
Company Profiles
- Apotex Inc.
- Cipla, Inc.
- Reddy’s Laboratory, Ltd.
- Glenmark Pharmaceutical, Ltd.
- Lupin, Ltd.
- Mylan N.V.
- Novartis AG
- Sun Pharmaceutical Industries, Ltd.
- Teva Pharmaceutical Industry, Ltd.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global imatinib drug market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/imatinib-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
